Selective GABA transporter inhibitors tiagabine and EF1502 exhibit mechanistic differences in their ability to modulate the ataxia and anticonvulsant action of the extrasynaptic GABAA receptor agonist gaboxadol

Journal of Pharmacology and Experimental Therapeutics

Volumn 338, Issue 1, 2011, Pages 214-219

  Madsen, Karsten K ^a   Ebert, Bjarke ^b   Clausen, Rasmus P ^a   Krogsgaard Larsen, Povl ^a   Schousboe, Arne ^a   White, H Steve ^c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b H LUNDBECK A S   (Denmark)

^c UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR ALPHA4; 4 AMINOBUTYRIC ACID CARRIER; GABOXADOL; N [4,4 BIS(3 METHYL 2 THIENYL) 3 BUTENYL] 3 HYDROXY 4 (METHYLAMINO) 4,5,6,7 TETRAHYDROBENZO[D]ISOXAZOL 3 OL; PROTEIN INHIBITOR; TIAGABINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; ATAXIA; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG MECHANISM; MALE; MOUSE; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; SEIZURE;

ANIMALS; ANTICONVULSANTS; ATAXIA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GABA AGONISTS; GABA PLASMA MEMBRANE TRANSPORT PROTEINS; ISOXAZOLES; MALE; MICE; NIPECOTIC ACIDS; RECEPTORS, GABA-A; SYNAPSES;

EID: 79959525532     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.179671     Document Type: Article

References (32)

1. Borden LA (1996) GABA transporter heterogeneity: pharmacology and cellular localization. Neurochem Int 29:335-356.
2. Borden LA, Smith KE, Gustafson EL, Branchek TA, and Weinshank RL (1995) Cloning and expression of a betaine/GABA transporter from human brain. J Neurochem 64:977-984.
3. A receptor α4 subunits mediate extrasynaptic inhibition in thalamus and dentate gyrus and the action of gaboxadol. Proc Natl Acad Sci USA 103:15230-15235.
4. Christensen AV and Larsen JJ (1982) Antinociceptive and anticonvulsive effect of THIP, a pure GABA agonist. Pol J Pharmacol Pharm 34:127-134. (Pubitemid 13173132)
5. Clausen RP, Moltzen EK, Perregaard J, Lenz SM, Sanchez C, Falch E, Frølund B, Bolvig T, Sarup A, Larsson OM, et al. (2005) Selective inhibitors of GABA uptake: synthesis and molecular pharmacology of 4-N-methylamino-4,5,6,7-tetrahydrobenzo[ d]isoxazol-3-ol analogues. Bioorg Med Chem 13:895-908. (Pubitemid 40103546)
6. Conti F, Melone M, De Biasi S, Minelli A, Brecha NC, and Ducati A (1998) Neuronal and glial localization of GAT-1, a high-affinity gamma-aminobutyric acid plasma membrane transporter, in human cerebral cortex: with a note on its distribution in monkey cortex. J Comp Neurol 396:51-63. (Pubitemid 28242451)
7. Conti F, Zuccarello LV, Barbaresi P, Minelli A, Brecha NC, and Melone M (1999) Neuronal, glial, and epithelial localization of γ-aminobutyric acid transporter 2, a high-affinity γ-aminobutyric acid plasma membrane transporter, in the cerebral cortex and neighboring structures. J Comp Neurol 409:482-494. (Pubitemid 29262257)
8. Cremers T and Ebert B (2007) Plasma and CNS concentrations of Gaboxadol in rats following subcutaneous administration. Eur J Pharmacol 562:47-52. (Pubitemid 46466750)
9. Dalby NO (2000) GABA-level increasing and anticonvulsant effects of three different GABA uptake inhibitors. Neuropharmacology 39:2399-2407.
10. Finney DJ (1971) Probit Analysis. Cambridge University Press, London.
11. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC.
12. Juhász G, Kékesi KA, Nyitrai G, Dobolyi A, Krogsgaard-Larsen P, and Schousboe A (1997) Differential effects of nipecotic acid and 4,5,6,7-tetrahydroisoxazolo[4,5-c]pyridin-3-ol on extracellular γ-aminobutyrate levels in rat thalamus. Eur J Pharmacol 331:139-144. (Pubitemid 27331442)
13. Krogsgaard-Larsen P, Frølund B, Liljefors T, and Ebert B (2004) GABA(A) agonists and partial agonists: THIP (Gaboxadol) as a non-opioid analgesic and a novel type of hypnotic. Biochem Pharmacol 68:1573-1580. (Pubitemid 39286462)
14. Liu QR, López-Corcuera B, Mandiyan S, Nelson H, and Nelson N (1993) Molecular characterization of four pharmacologically distinct gamma-aminobutyric acid transporters in mouse brain [corrected]. J Biol Chem 268:2106-2112. (Pubitemid 23033620)
15. LOEWE S (1953) The problem of synergism and antagonism of combined drugs. Arzneimittelforschung 3:285-290.
16. Madsen KK, Clausen RP, Larsson OM, Krogsgaard-Larsen P, Schousboe A, and White HS (2009) Synaptic and extrasynaptic GABA transporters as targets for anti-epileptic drugs. J Neurochem 109 (Suppl 1):139-144.
17. Madsen KK, White HS, and Schousboe A (2010) Neuronal and non-neuronal GABA transporters as targets for antiepileptic drugs. Pharmacol Ther 125:394-401.
18. Minelli A, DeBiasi S, Brecha NC, Zuccarello LV, and Conti F (1996) GAT-3, a high-affinity GABA plasma membrane transporter, is localized to astrocytic processes, and it is not confined to the vicinity of GABAergic synapses in the cerebral cortex. J Neurosci 16:6255-6264. (Pubitemid 26313999)
19. Nielsen EB, Suzdak PD, Andersen KE, Knutsen LJ, Sonnewald U, and Braestrup C (1991) Characterization of tiagabine (NO-328), a new potent and selective GABA uptake inhibitor. Eur J Pharmacol 196:257-266.
20. Nusser Z and Mody I (2002) Selective modulation of tonic and phasic inhibitions in dentate gyrus granule cells. J Neurophysiol 87:2624-2628. (Pubitemid 34670732)
21. Schousboe A (2003) Role of astrocytes in the maintenance and modulation of glutamatergic and GABAergic neurotransmission. Neurochem Res 28:347-352.
22. Schousboe A and White HS (2009) Glial modulation of excitability via glutamate and GABA transporters, in Encyclopedia of Basic Epilepsy Research (Schwartzkroin PA ed) pp 397-401, Academic Press, Oxford.
23. Stell B and Mody I (2003) A tale of timing and transport. Neuron 39:729-730. (Pubitemid 37088083)
24. Stórustovu SI and Ebert B (2006) Pharmacological characterization of agonists at δ-containing GABAA receptors: Functional selectivity for extrasynaptic receptors is dependent on the absence of γ2. J Pharmacol Exp Ther 316:1351-1359. (Pubitemid 43345312)
25. Tallarida RJ (1992) Statistical analysis of drug combinations for synergism. Pain 49:93-97.
26. Tallarida RJ, Stone DJ Jr, and Raffa RB (1997) Efficient designs for studying synergistic drug combinations. Life Sci 61:PL 417-PL 425.
27. Wafford KA and Ebert B (2006) Gaboxadol-a new awakening in sleep. Curr Opin Pharmacol 6:30-36.
28. Wei W, Zhang N, Peng Z, Houser CR, and Mody I (2003) Perisynaptic localization of δ subunit-containing GABAA receptors and their activation by GABA spillover in the mouse dentate gyrus. J Neurosci 23:10650-10661. (Pubitemid 37485279)
29. White HS, Hunt J, Wolf HH, Swinyard EA, Falch E, Krogsgaard-Larsen P, and Schousboe A (1993) Anticonvulsant activity of the gamma-aminobutyric acid uptake inhibitor N-4,4-diphenyl-3-butenyl-4,5,6,7-tetrahydroisoxazolo[4,5-c] pyridin-3-ol. Eur J Pharmacol 236:147-149. (Pubitemid 23146862)
30. White HS, Sarup A, Bolvig T, Kristensen AS, Petersen G, Nelson N, Pickering DS, Larsson OM, Frølund B, Krogsgaard-Larsen P, et al. (2002) Correlation between anticonvulsant activity and inhibitory action on glial γ-aminobutyric acid uptake of the highly selective mouse γ-aminobutyric acid transporter 1 inhibitor 3-hydroxy-4-amino-4,5,6,7- tetrahydro-1,2-benzisoxazole and its N-alkylated analogs. J Pharmacol Exp Ther 302:636-644. (Pubitemid 34787230)
31. White HS, Watson WP, Hansen SL, Slough S, Perregaard J, Sarup A, Bolvig T, Petersen G, Larsson OM, Clausen RP, et al. (2005) First demonstration of a functional role for central nervous system betaine/γ-aminobutyric acid transporter (mGAT2) based on synergistic anticonvulsant action among inhibitors of mGAT1 and mGAT2. J Pharmacol Exp Ther 312:866-874. (Pubitemid 40189590)
32. Zhu XM and Ong WY (2004) A light and electron microscopic study of betaine/GABA transporter distribution in the monkey cerebral neocortex and hippocampus. J Neurocytol 33:233-240.